Goldman Sachs Downgrades Cepheid to 'Neutral'

In a research note, the investment house cited concerns about Cepheid's high price-to-sale ratio but said that the firm's installed base is expected to grow 27 percent year over year in 2011.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories